$INCY news
The latest INCY stock news: headlines, filings, AI summaries and sentiment for $INCY, updated around the clock.
- Major US Indexes and Biotech Sector Rally Following Election and Strong Earnings
- Oppenheimer Upgrades Incyte to Outperform Amid Growth Potential Beyond Jakafi
- Wall Street Analyst Updates: Rivian Upgraded, Intel and Reddit Downgraded
- Incyte Reports 14% Revenue Growth in Q3 2026 Driven by Opzelura and Oncology Sales
- INCYTE CORP - 10-Q Filing
- Incyte Provides 2026 Net Sales Outlook and Raises Opzelura Guidance
- INCYTE CORP - 8-K Filing
- Incyte Scheduled to Report Q3 2026 Earnings Results
- FDA Approves Mirum and Incyte's Atebrioz for Rare Bone Disorder FOP
- Specialised Therapeutics to Commercialize Incyte's Opzelura in Australia
- INCYTE CORP - 8-K Filing
- FDA Approves Regeneron's Rare-Disease Drug Pasatru Despite Small Market Potential
- Incyte Stock Performance Outpaces Market Amid Strong Earnings and Analyst Upgrades
- INCYTE CORP - 10-Q Filing
- Incyte Reports Strong Q2 Earnings and Raises Full-Year Revenue Guidance
- INCYTE CORP - 8-K Filing
- Halozyme and Incyte Collaborate on Subcutaneous INCA033989 Using ENHANZE Technology
- Halozyme and Incyte Collaborate on Enhanze Technology for Myeloproliferative Neoplasm Candidate
- Eli Lilly, Incyte, and CSL Receive EU Drug Recommendations
- INCYTE CORP - 8-K Filing
- Incyte Acquires Vega Therapeutics in $1.25B Deal
- INCYTE CORP - 8-K Filing
- Incyte Near $2 Billion Deal for Star Therapeutics
- Incyte's Monjuvi Shows Improved Cancer-Free Survival in Lymphoma Trial
- Incyte Corporation (INCY) Stock Performance and Q1 Earnings Analysis
- Incyte Expands AI Drug Discovery Partnership with Genesis Molecular AI
- Zimmer Biomet CFO Resigns, Interim Replacement Named
- Incyte Reports Q1 2026 Earnings Results with Revenue Growth and Key Product Performance
- Incyte Reports Q2 2025 Earnings with Revenue Growth and Guidance Increase
- Incyte Reports Strong Q1 2026 Earnings with Revenue Growth and Pipeline Progress
- Incyte Appoints Suketu Upadhyay as New CFO
- Incyte Reports Q4 2024 Earnings with Revenue Growth and Guidance for 2025
- RBC Capital Increases Price Target for Incyte Corporation to $95
- Adagene and Incyte Collaborate on Combination Therapy for Colorectal Cancer